Varenicline-induced manic episode

Abstract

Varenicline is a novel antismoking agent that reduces cravings and blocks pleasure of nicotine by serving as a partial agonist to the nicotinic receptor. Varenicline has been associated with some important psychiatric adverse effects in patients with psychiatric history. However, varenicline related manic episode has not been reported so far in the literature in patients with no psychiatric history. Here we report a manic episode case with psychotic features developed in an individual on varenicline with no personal and family psychiatric history.

Keywords

• -

Varenikline bağlı manik dönem

Öz

Vareniklin, nikotinik reseptörlerde kısmi agonist etki göstererek nikotin isteğini bloke eden ve aşermeyi azaltan yeni bir antismoking (sigara içme karşıtı) ilaçtır. Psikiyatrik öyküsü olan hastalarda bazı önemli olumsuz psikiyatrik etkilerle ilişkilendirilir. Bugüne kadar, psikiyatrik öyküsü olmayan hastalarda varenikline bağlı manik dönem bildirilmemiştir. Bu yayında ilk kez, ailesinde ve kendisinde psikiyatrik hastalık öyküsü olmayan bir bireyde, varenikline bağlı psikotik bulgulu manik dönem tanımlanmaktadır.

Anahtar Kelimeler

• variniklin, mani, nikotin

References

1. Rosecrans JA: The biobehavioral effects of nicotine: interaction with brain neurochemical systems, in The Clinical Management of Nicotine Dependence. Edited by Cocores JA. New York, SpringerVerlag, 1991,pp 53-653.
2. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164:1269-1270.
3. Food and Drug Administration. FDA Med Watch Alert, Varenicline (marketed as Chantix): Information, February 1, 2008, and November 20, 2007. Available at www.fda.gov/cder/drug/ infopage/varenicline/default.htm. Accessed April 20, 2008.
4. Freedman R. Exacerbation of schizophrenia by varenicline [letter]. Am J Psychiatry. 2007;164:1269.
5. Pumariega AJ, Nelson R, Rotenberg L, Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr. 2008;13(6):511-514. 7. Coe J, Brooks P, Vertelino M, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-3477.
6. Coe J, Brooks P, Vertelino M, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-3477.
7. Gonzales D, Rennard S, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustainedrelease bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
8. Jorenby DE, Hays JR, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.

9. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
10. Fadi Alhatem, MD and James E. Black, MD, PhD. VareniclineInduced Mania in a Bipolar Patient. Clin Neuropharm 2009;32: 117-118